- Home
- KNRX vs TOVX Comparison
KNRX vs TOVX Comparison
Compare KNRX & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KNRX | TOVX |
|---|---|---|
| Founded | 2009 | 2001 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5M | 11.1M |
| IPO Year | 2023 | 2012 |
Fundamental Metrics
Financial Performance| Metric | KNRX | TOVX |
|---|---|---|
| Price | $0.18 | $0.19 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | ★ 13.6M | 396.9K |
| Earning Date | 11-03-2026 | 08-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 89.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.15 | $0.16 |
| 52 Week High | $3.45 | $0.49 |
Technical Indicators
Market Signals| Indicator | KNRX | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 43.38 | 35.07 |
| Support Level | $0.15 | $0.17 |
| Resistance Level | $0.49 | $0.25 |
| Average True Range (ATR) | 0.02 | 0.01 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 26.07 | 4.75 |
Price Performance
Historical ComparisonAbout KNRX KNOREX LTD. Class A Ordinary Shares
Knorex Ltd is a B2B technology company providing programmatic advertising products and solutions to marketers to streamline and automate their advertising and marketing workflows. The company's product, Knorex XPOSM, is a self-service, enterprise-grade cloud platform with a suite of advertising management and execution (AMX) applications.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.